Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying

Aclaris Therapeutics和其他3支低於2美元的股票正在被內部人士購買

Benzinga · 07/23 19:31

The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

BranchOut Food

The Trade: BranchOut Food Inc. (NASDAQ:BOF) Director Byron Riche Jones bought a total of 41,755 shares at an average price of $0.99. To acquire these shares, it cost around $41,337.
What's Happening: On June 26, Branchout Food announced the pricing of its $1.4 million underwritten public offering of 1.75 million shares of common stock at $0.80 per share.
What BranchOut Food Does: Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders.

Innovative Food Holdings

The Trade: Innovative Food Holdings, Inc. (OTC:IVFH) Director Denver Johnson Smith acquired a total of 350,000 shares at an average price of $1.20. To acquire these shares, it cost around $420,000.
What's Happening: On May 14, the company said revenues in the first quarter fell 5.7% to $15.7 million.
What Innovative Food Holdings Does: Innovative Food Holdings Inc through its subsidiaries is engaged in the distribution of perishables and specialty food products.

Crown Equity Holdings

The Trade: Crown Equity Holdings Inc. (OTC:CRWE) Marketing/Merger/Acq. Officer Jamie Hadfield acquired a total of 5,000 shares at an average price of $0.25. The insider spent around $1,250 to buy those shares.
What's Happening: On June 14, Crown Equity named Ahmad Moradi as the new Chairman of the Board and Chief Strategic & Science Officer.
What Crown Equity Holdings Does: Crown Equity Holdings Inc offers services to companies seeking to become public entities in the United States.

Aclaris Therapeutics

The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard acquired a total of 154,722 shares at an average price of $1.31. The insider spent around $201,808 to buy those shares.
What's Happening: On July 16, Aclaris Therapeutics announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.
What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.

Read More:

Wall Street's Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields

The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

週一，道瓊斯指數上漲超過100點。當內部人士買賣股票時，這表明他們對公司前景的信心或擔憂。有意投資或交易低價股的投資者和交易者可以考慮這一因素作爲其整體投資或交易決策的因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。

BranchOut Food

BranchOut Food

The Trade: BranchOut Food Inc. (NASDAQ:BOF) Director Byron Riche Jones bought a total of 41,755 shares at an average price of $0.99. To acquire these shares, it cost around $41,337.
What's Happening: On June 26, Branchout Food announced the pricing of its $1.4 million underwritten public offering of 1.75 million shares of common stock at $0.80 per share.
What BranchOut Food Does: Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders.

交易：BranchOut Food Inc.（納斯達克股票代碼：BOF）董事Byron Riche Jones以平均價格0.99美元購買了共計41,755股股票。要獲得這些股票，大約需要花費41,337美元。
What's Happening：6月26日，Branchout Food宣佈其14萬美元的公開發行價格爲每股0.8美元，共發行175萬股普通股。
Branchout Food Inc從事植物基礎的、脫水的水果和蔬菜零食和粉末的開發、市場營銷、銷售和分銷。

Innovative Food Holdings

Innovative Food Holdings

The Trade: Innovative Food Holdings, Inc. (OTC:IVFH) Director Denver Johnson Smith acquired a total of 350,000 shares at an average price of $1.20. To acquire these shares, it cost around $420,000.
What's Happening: On May 14, the company said revenues in the first quarter fell 5.7% to $15.7 million.
What Innovative Food Holdings Does: Innovative Food Holdings Inc through its subsidiaries is engaged in the distribution of perishables and specialty food products.

交易：Innovative Food Holdings, Inc.（場外交易股票代碼：IVFH）董事Denver Johnson Smith以平均價格1.2美元購買了共計35萬股股票。要獲得這些股票，大約需要花費42萬美元。
What's Happening：5月14日，該公司表示，第一季度收入下降了5.7％，至1570萬美元。
通過其子公司Innovative Food Holdings Inc，從事易腐和特殊食品產品的分銷。

Crown Equity Holdings

Crown Equity Holdings

The Trade: Crown Equity Holdings Inc. (OTC:CRWE) Marketing/Merger/Acq. Officer Jamie Hadfield acquired a total of 5,000 shares at an average price of $0.25. The insider spent around $1,250 to buy those shares.
What's Happening: On June 14, Crown Equity named Ahmad Moradi as the new Chairman of the Board and Chief Strategic & Science Officer.
What Crown Equity Holdings Does: Crown Equity Holdings Inc offers services to companies seeking to become public entities in the United States.

交易：Crown Equity Holdings Inc.（場外交易股票代碼：CRWE）營銷/合併/收購高級主管Jamie Hadfield以平均價格0.25美元購買了共計5,000股股票。該內部人士花費約1250美元購買這些股票。
What's Happening：6月14日，Crown Equity任命Ahmad Moradi爲董事會主席兼首席戰略和科學官。
Crown Equity Holdings Inc爲尋求在美國上市的公司提供服務。

Aclaris Therapeutics

aclaris therapeutics

The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard acquired a total of 154,722 shares at an average price of $1.31. The insider spent around $201,808 to buy those shares.
What's Happening: On July 16, Aclaris Therapeutics announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.
What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.

交易：Aclaris Therapeutics, Inc.（納斯達克股票代碼：ACRS）10％股東Braden Michael Leonard以平均價格1.31美元購買了總共154,722股股票。該內部人士花費約20.18萬美元購買這些股票。
What's Happening：7月16日，Aclaris Therapeutics宣佈將OLUMIANt特許權和里程碑轉讓給OMERS Life Sciences，轉讓價格高達3150萬美元。
aclaris therapeutics inc是一家在美國運營的臨床階段生物製藥公司。

Read More:

閱讀更多：

Wall Street's Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields

華爾街最準確的分析師表示，建議持有這3只能源股票，其股息收益率超過5%。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。